AMLX has had major setbacks in its lifecycle, including the voluntary withdrawal of an approved drug. Click here to find out ...

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that management will participate in the following upcoming investor conferences, which are being ...

Amylyx Pharmaceuticals (NASDAQ:AMLX – Get Free Report) is expected to be releasing its earnings data before the market opens ...

Amylyx Pharmaceuticals, Inc. (AMLX) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates ...

A live webcast of both presentations can be accessed under "Events and Presentations" in the Investor section of the Company’s website, ...

Earnings Estimate Revisions for Amylyx Pharmaceuticals This company is expected to earn -$4.29 per share for the fiscal year ending December 2024, which represents a year-over-year change of -712.9%.

2025年2月26日， Amylyx（AMLX）披露1笔公司内部人交易情况。高管Mazzariello Gina于2025年2月24日卖出4169股。 Amylyx Pharmaceuticals, ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that management will participate in ...

NEW YORK CITY, NY / ACCESS Newswire / February 14, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of ...